Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: rejeski k. Cytotherapy. 2023 Sep;25(9):986-992. doi: 10.1016/j.jcyt.2023.03.007. Epub 2023 Apr 11. Cytotherapy. 2023. PMID: 37055322
Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on 18F-FDG PET/CT.
Winkelmann M, Rejeski K, Unterrainer M, Schmidt C, Ruzicka M, Ricke J, Rudelius M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: rejeski k. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1692-1693. doi: 10.1007/s00259-020-05000-9. Epub 2020 Aug 19. Eur J Nucl Med Mol Imaging. 2021. PMID: 32814980 Free PMC article. No abstract available.
Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report.
Rejeski K, Kunz WG, Rudelius M, Bücklein V, Blumenberg V, Schmidt C, Karschnia P, Schöberl F, Dimitriadis K, von Baumgarten L, Stemmler J, Weigert O, Dreyling M, von Bergwelt-Baildon M, Subklewe M. Rejeski K, et al. BMC Infect Dis. 2021 Jan 28;21(1):121. doi: 10.1186/s12879-020-05755-4. BMC Infect Dis. 2021. PMID: 33509115 Free PMC article.
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Bücklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain MD, Subklewe M. Rejeski K, et al. Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543. Blood. 2021. PMID: 34166502 Free PMC article.
Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment.
Schoeberl F, Tiedt S, Schmitt A, Blumenberg V, Karschnia P, Burbano VG, Bücklein VL, Rejeski K, Schmidt C, Busch G, von Bergwelt-Baildon M, Tonn JC, Schmitt M, Subklewe M, von Baumgarten L. Schoeberl F, et al. Among authors: rejeski k. Blood Adv. 2022 May 24;6(10):3022-3026. doi: 10.1182/bloodadvances.2021006144. Blood Adv. 2022. PMID: 35042236 Free PMC article.
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
Dos Santos DMC, Rejeski K, Winkelmann M, Liu L, Trinkner P, Günther S, Bücklein VL, Blumenberg V, Schmidt C, Kunz WG, Von Bergwelt-Baildon M, Theurich S, Subklewe M. Dos Santos DMC, et al. Among authors: rejeski k. Haematologica. 2022 Sep 1;107(9):2096-2107. doi: 10.3324/haematol.2021.280189. Haematologica. 2022. PMID: 35172565 Free PMC article.
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma.
Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, Lopez-Corral L, van Aalderen M, Kwon M, Martínez-Cibrian N, Bramanti S, Reguera-Ortega JL, Camacho-Arteaga L, Schmidt C, Marín-Niebla A, Kersten MJ, Martin Garcia-Sancho A, Zinzani PL, Corradini P, van Meerten T, Subklewe M, Barba P. Iacoboni G, et al. Among authors: rejeski k. Blood Adv. 2022 Jun 28;6(12):3606-3610. doi: 10.1182/bloodadvances.2021006922. Blood Adv. 2022. PMID: 35271707 Free PMC article. No abstract available.
Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
Karschnia P, Rejeski K, Winkelmann M, Schöberl F, Bücklein VL, Blumenberg V, Schmidt C, Blobner J, von Bergwelt-Baildon M, Tonn JC, Kunz WG, Subklewe M, von Baumgarten L. Karschnia P, et al. Among authors: rejeski k. Neurology. 2022 May 24;98(21):884-889. doi: 10.1212/WNL.0000000000200608. Epub 2022 Mar 29. Neurology. 2022. PMID: 35351785 Free PMC article.
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C, Blumenberg V, Hoster E, Bullinger L, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Barba P, Jain MD, Subklewe M. Rejeski K, et al. J Immunother Cancer. 2022 May;10(5):e004475. doi: 10.1136/jitc-2021-004475. J Immunother Cancer. 2022. PMID: 35580927 Free PMC article.
61 results